(Q33419580)

English

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

0 references

1 reference

based on heuristic

inferred from title

chronic lymphocytic leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Christian Geisler

19

object named as

Christian H Geisler

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Carsten Utoft Niemann

object named as

Carsten U Niemann

6

0 references

12

object named as

Jade Jones

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Stefania Pittaluga

14

object named as

Stefania Pittaluga

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Maryalice Stetler-Stevenson

15

object named as

Maryalice Stetler-Stevenson

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Mohammed Z H Farooqui

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Janet Valdez

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sabrina Martyr

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Georg Aue

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Nakhle Saba

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sarah E M Herman

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Xin Tian

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Gerald Marti

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Susan Soto

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Thomas E Hughes

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Andrew Lipsky

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Constance Yuan

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yuh Shan Lee

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lone B Pedersen

18

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Katherine R Calvo

20

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Diane C Arthur

21

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Irina Maric

22

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Richard Childs

23

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Neal S Young

24

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Adrian Wiestner

25

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

31 December 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

169-176

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

Microenvironmental interactions in chronic lymphocytic leukemia: the master role of CD49d.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

Ibrutinib resistance in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

How the microenvironment wires the natural history of chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

17p deletion in chronic lymphocytic leukemia: risk stratification and therapeutic approach

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

Bruton tyrosine kinase (BTK) and its role in B-cell malignancy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

What is the best frontline therapy for patients with CLL and 17p deletion?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

21 June 2018

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

31 October 2018

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

31 October 2018

Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4342187

31 October 2018

Identifiers

10.1016/S1470-2045(14)71182-9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33419580&oldid=2049596283"